Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib, Alopecia Areata, Date of authorisation: 15/09/2023, Status: Authorised
For the full list of side effects and restrictions with Litfulo, see the package leaflet.
The most common side effects with Litfulo (which may affect up to 1 in 10 people) include diarrhoea, acne, upper respiratory tract (nose and throat) infections, urticaria (itchy rash), rash, folliculitis (inflammation of hair follicles) and dizziness.
Litfulo must not be used in patients with active serious infections, including tuberculosis, or severe liver problems. The medicine also must not be used in women who are pregnant or breast-feeding.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
